Insights | CRB

During a crisis, moving drugs to market requires a strong HVAC strategy

As the global pandemic brings new attention to emerging therapies, the biopharmaceutical industry shouldn’t overlook HVAC design for contamination control.

6 considerations for scaling up an industrial biotechnology process

Industrial biotechnology processes face a unique set of challenges when it comes to scale-up.

Preventing the next pandemic: mRNA vaccines and siRNA oligo therapies

Investing in promising new pharmaceutical platforms like oligonucleotide therapies could reduce the gap between first detection and total eradication in future pandemics.

4 strategies of successful project execution

A lean approach to project execution relies on four steps for success.

Developing new tools in the pandemic response toolbox

There’s a lot to be learned from the COVID-19 pandemic, including how we can be better prepared for future pandemics.

Viral vectors—beyond the yellow brick road

The science of viral vector manufacturing is generating a lot of excitement, and companies in this space are under pressure to move fast and make cost-effective decisions; this can occasionally result in speed at the expense of due diligence.

Vaccines—our best long-term defense

Not a treatment, but a cure, vaccines are extremely important because they help us develop lifelong immunity to diseases.

Multimodal ATMP facilities to satisfy growing demand

Multimodal manufacturing optimizes product combinations based on manufacturing and regulatory similarity and compatibility. Manufacturers must produce a variety of Advanced Therapy Medicinal Products (ATMPs) quickly and efficiently. Why not design a multi-modal ATMP facility?

The greatest hazard for incubator labs? Inadequately managed hazardous chemicals

Developers creating multi-tenant spaces for life science startups need to consider something most other industries don’t: how hazardous chemicals play a role in their tenants’ work and the design of the building.